Emerging role of liver X receptors in cardiac pathophysiology and heart failure

Agonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, Diaz M, Gallardo G, de Galarreta CR, Salazar J, Lopez F, Edwards P, Parks J, Andujar M, Tontonoz P, Castrillo A (2009) Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31:245–258. doi:10.1016/j.immuni.2009.06.018 Albers M, Blume B, Schlueter T, Wright MB, Kober I, Kremoser C, Deuschle U, Koegl M (2006) A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J Biol Chem 281:4920–4930 (M510101200 [pii]) Antonson P, Jakobsson T, Almlof T, Guldevall K, Steffensen KR, Gustafsson JA (2008) RAP250 is a coactivator in the transforming growth factor beta signaling pathway that interacts with Smad2 and Smad3. J Biol Chem 283:8995–9001. doi:10.1074/jbc.M707203200 Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M (1994) A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 14:7025–7035 Ashrafian H, Frenneaux MP, Opie LH (2007) Metabolic mechanisms in heart failure. Circulation 116:434–448 (116/4/434 [pii]) Baranowski M, Zabielski P, Blachnio-Zabielska AU, Harasim E, Chabowski A, Gorski J (2014) Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation. Cell Physiol Biochem 33:1047–1057. doi:10.1159/000358675 Beaven SW, Matveyenko A, Wroblewski K, Chao L, Wilpitz D, Hsu TW, Lentz J, Drew B, Hevener AL, Tontonoz P (2013) Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab 18:106–117. doi:10.1016/j.cmet.2013.04.021 Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H, Tontonoz P (2011) Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 140:1052–1062. doi:10.1053/j.gastro.2010.11.053 Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P (2008) LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134:97–111. doi:10.1016/j.cell.2008.04.052 Beyer C, Huang J, Beer J, Zhang Y, Palumbo-Zerr K, Zerr P, Distler A, Dees C, Maier C, Munoz L, Kronke G, Uderhardt S, Distler O, Jones S, Rose-John S, Oravecz T, Schett G, Distler JH (2014) Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204401 Blaschke F, Leppanen O, Takata Y, Caglayan E, Liu J, Fishbein MC, Kappert K, Nakayama KI, Collins AR, Fleck E, Hsueh WA, Law RE, Bruemmer D (2004) Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 95:e110–e123 (01.RES.0000150368.56660.4f [pii]) Bories G, Colin S, Vanhoutte J, Derudas B, Copin C, Fanchon M, Daoudi M, Belloy L, Haulon S, Zawadzki C, Jude B, Staels B, Chinetti-Gbaguidi G (2013) Liver X receptor activation stimulates iron export in human alternative macrophages. Circ Res 113:1196–1205. doi:10.1161/CIRCRESAHA.113.301656 Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH (2013) Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34:1424–1431. doi:10.1093/eurheartj/eht066 Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 128:388–400. doi:10.1161/CIRCULATIONAHA.113.001878 Calkin AC, Tontonoz P (2010) Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 30:1513–1518. doi:10.1161/ATVBAHA.109.191197 Cannon MV, Sillje HH, Sijbesma JW, Vreeswijk-Baudoin I, Ciapaite J, van der Sluis B, van Deursen J, Silva GJ, de Windt LJ, Gustafsson JA, van der Harst P, van Gilst WH, de Boer RA (2015) Cardiac LXRalpha protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med 7:1229–1243. doi:10.15252/emmm.201404669 Cannon MV, Yu H, Candido WM, Dokter MM, Lindstedt EL, Sillje HH, van Gilst WH, de Boer RA (2015) The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. Eur J Heart Fail 17:273–282. doi:10.1002/ejhf.243 Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, Miller AR, Dai J, Foxworthy P, Gao H, Ryan TP, Jiang XC, Burris TP, Eacho PI, Etgen GJ (2003) Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278:1131–1136. doi:10.1074/jbc.M210208200 Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P (2003) Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 278:10443–10449. doi:10.1074/jbc.M213071200 Cha JY, Repa JJ (2007) The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 282:743–751 (M605023200 [pii]) Chen J, Cui X, Zacharek A, Roberts C, Chopp M (2009) eNOS mediates TO90317 treatment-induced angiogenesis and functional outcome after stroke in mice. Stroke 40:2532–2538. doi:10.1161/STROKEAHA.108.545095 Chen J, Zhao L, Sun D, Narsinh K, Li C, Zhang Z, Qi S, Wei G, Li W, Guo W, Cao F (2012) Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice. Inflamm Res 61:1299–1307. doi:10.1007/s00011-012-0529-4 Cheng O, Ostrowski RP, Liu W, Zhang JH (2010) Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaB. Neuroscience 166:1101–1109. doi:10.1016/j.neuroscience.2010.01.024 Cheng Y, Feng Y, Zhu M, Yan B, Fu S, Guo J, Hu J, Song X, Guo S, Liu G (2014) Synthetic liver X receptor agonist T0901317 attenuates high glucose-induced oxidative stress, mitochondrial damage and apoptosis in cardiomyocytes. Acta Histochem 116:214–221. doi:10.1016/j.acthis.2013.07.007 Cheng Y, Liu G, Pan Q, Guo S, Yang X (2011) Elevated expression of liver X receptor alpha (LXRalpha) in myocardium of streptozotocin-induced diabetic rats. Inflammation 34:698–706. doi:10.1007/s10753-010-9281-5 Chisholm JW, Hong J, Mills SA, Lawn RM (2003) The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 44:2039–2048. doi:10.1194/jlr.M300135-JLR200 Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, Kim JB (2007) Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic beta-cells. Diabetes 56:1534–1543 (db06-1059 [pii]) Chuu CP, Lin HP (2010) Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res 30:3643–3648 (30/9/3643 [pii]) Commerford SR, Vargas L, Dorfman SE, Mitro N, Rocheford EC, Mak PA, Li X, Kennedy P, Mullarkey TL, Saez E (2007) Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol Endocrinol 21:3002–3012 (me.2007-0156 [pii]) Cozzone D, Debard C, Dif N, Ricard N, Disse E, Vouillarmet J, Rabasa-Lhoret R, Laville M, Pruneau D, Rieusset J, Lefai E, Vidal H (2006) Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia 49:990–999. doi:10.1007/s00125-006-0140-8 Crisafulli C, Di Paola R, Mazzon E, Paterniti I, Galuppo M, Genovese T, Bramanti P, Cappellani A, Cuzzocrea S (2010) Liver X receptor agonist treatment reduced splanchnic ischemia and reperfusion injury. J Leukoc Biol 87:309–321. doi:10.1189/jlb.0609438 Dahlman I, Nilsson M, Jiao H, Hoffstedt J, Lindgren CM, Humphreys K, Kere J, Gustafsson JA, Arner P, Dahlman-Wright K (2006) Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet Genomics 16:881–889. doi:10.1097/01.fpc.0000236334.49422.48 Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI (2003) Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha. J Biol Chem 278:48283–48291. doi:10.1074/jbc.M302287200 Dave VP, Kaul D, Sharma Y, Bhattacharya R (2009) Functional genomics of blood cellular LXR-alpha gene in human coronary heart disease. J Mol Cell Cardiol 46:536–544. doi:10.1016/j.yjmcc.2008.12.020 De Boer RA, Pinto YM, Van Veldhuisen DJ (2003) The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10:113–126. doi:10.1038/sj.mn.7800188 De Boussac H, Alioui A, Viennois E, Dufour J, Trousson A, Vega A, Guy L, Volle DH, Lobaccaro JM, Baron S (2013) Oxysterol receptors and their therapeutic applications in cancer conditions. Expert Opin Ther Targets 17:1029–1038. doi:10.1517/14728222.2013.820708 Delvecchio CJ, Bilan P, Radford K, Stephen J, Trigatti BL, Cox G, Parameswaran K, Capone JP (2007) Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol Endocrinol 21:1324–1334 (me.2007-0017 [pii]) Dobaczewski M, Chen W, Frangogiannis NG (2011) Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 51:600–606. doi:10.1016/j.yjmcc.2010.10.033 Efanov AM, Sewing S, Bokvist K, Gromada J (2004) Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53(Suppl 3):S75–S78 (53/suppl_3/S75 [pii]) Fang L, Choi SH, Baek JS, Liu C, Almazan F, Ulrich F, Wiesner P, Taleb A, Deer E, Pattison J, Torres-Vazquez J, Li AC, Miller YI (2013) Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature 498:118–122. doi:10.1038/nature12166 Fernandez-Veledo S, Vila-Bedmar R, Nieto-Vazquez I, Lorenzo M (2009) c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J Clin Endocrinol Metab 94:3583–3593. doi:10.1210/jc.2009-0558 Gabbi C, Kong X, Suzuki H, Kim HJ, Gao M, Jia X, Ohnishi H, Ueta Y, Warner M, Guan Y, Gustafsson JA (2012) Central diabetes insipidus associated with impaired renal aquaporin-1 expression in mice lacking liver X receptor beta. Proc Natl Acad Sci USA 109:3030–3034. doi:10.1073/pnas.1200588109 Galderisi M, Anderson KM, Wilson PW, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68:85–89 (0002-9149(91)90716-X [pii]) Gerin I, Dolinsky VW, Shackman JG, Kennedy RT, Chiang SH, Burant CF, Steffensen KR, Gustafsson JA, MacDougald OA (2005) LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem 280:23024–23031 (M412564200 [pii]) Geyeregger R, Zeyda M, Stulnig TM (2006) Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci 63:524–539. doi:10.1007/s00018-005-5398-3 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2014) Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 129:e28–e292. doi:10.1161/01.cir.0000441139.02102.80 Gong H, He J, Lee JH, Mallick E, Gao X, Li S, Homanics GE, Xie W (2009) Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. J Biol Chem 284:30113–30121. doi:10.1074/jbc.M109.047753 Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, Romijn JA, Groot PH, Reijngoud DJ, Kuipers F (2005) Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 289:E829–E838 (00165.2005 [pii]) Hayashi T, Kotani H, Yamaguchi T, Taguchi K, Iida M, Ina K, Maeda M, Kuzuya M, Hattori Y, Ignarro LJ (2014) Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes. Proc Natl Acad Sci USA 111:1168–1173. doi:10.1073/pnas.1322153111 Hazra S, Rasheed A, Bhatwadekar A, Wang X, Shaw LC, Patel M, Caballero S, Magomedova L, Solis N, Yan Y, Wang W, Thinschmidt JS, Verma A, Li Q, Levi M, Cummins CL, Grant MB (2012) Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes. Diabetes 61:3270–3279. doi:10.2337/db11-1596 He Q, Pu J, Yuan A, Lau WB, Gao E, Koch WJ, Ma XL, He B (2014) Activation of liver-x-receptor alpha but not liver-x-receptor beta protects against myocardial ischemia/reperfusion injury. Circ Heart Fail 7:1032–1041. doi:10.1161/CIRCHEARTFAILURE.114.001260 He Q, Pu J, Yuan A, Yao T, Ying X, Zhao Y, Xu L, Tong H, He B (2014) Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice. Cardiovasc Diabetol 13:149 (s12933-014-0149-0 [pii]) Herzog B, Hallberg M, Seth A, Woods A, White R, Parker MG (2007) The nuclear receptor cofactor, receptor-interacting protein 140, is required for the regulation of hepatic lipid and glucose metabolism by liver X receptor. Mol Endocrinol 21:2687–2697 (me.2007-0213 [pii]) Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933–1943. doi:10.1016/S0140-6736(14)60107-0 Hong C, Tontonoz P (2014) Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov 13:433–444. doi:10.1038/nrd4280 Huang C (2014) Natural modulators of liver X receptors. J Integr Med 12:76–85 (S2095-4964(14)60013-3 [pii]) Imayama I, Ichiki T, Patton D, Inanaga K, Miyazaki R, Ohtsubo H, Tian Q, Yano K, Sunagawa K (2008) Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 51:1631–1636. doi:10.1161/HYPERTENSIONAHA.107.106963 Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L (2005) Insulin resistance and risk of congestive heart failure. JAMA 294:334–341 (294/3/334 [pii]) Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR (2012) Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 33:394–404. doi:10.1016/j.tips.2012.03.013 Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383:728–731. doi:10.1038/383728a0 Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD (2011) Targeting fatty acid and carbohydrate oxidation—a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813:1333–1350. doi:10.1016/j.bbamcr.2011.01.015 Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O’connell RM, Cheng G, Saez E, Miller JF, Tontonoz P (2004) LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119:299–309 (S0092867404009419 [pii]) Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9:213–219. doi:10.1038/nm820 Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99:7604–7609. doi:10.1073/pnas.112059299 Kalaany NY, Gauthier KC, Zavacki AM, Mammen PP, Kitazume T, Peterson JA, Horton JD, Garry DJ, Bianco AC, Mangelsdorf DJ (2005) LXRs regulate the balance between fat storage and oxidation. Cell Metab 1:231–244 (S1550-4131(05)00060-4 [pii]) Kantor PF, Dyck JR, Lopaschuk GD (1999) Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci 318:3–14 Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M (2014) Activation of liver X receptor decreases atherosclerosis in Ldlr(-)/(-) mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler Thromb Vasc Biol 34:279–284. doi:10.1161/ATVBAHA.113.302781 Kase ET, Wensaas AJ, Aas V, Hojlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan AC, Gaster M (2005) Skeletal muscle lipid accumulation in type 2 diabetes may involve the liver X receptor pathway. Diabetes 54:1108–1115 Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X (2009) Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 49:643–649. doi:10.1177/0091270009335768 Ketterer C, Mussig K, Machicao F, Stefan N, Fritsche A, Haring HU, Staiger H (2011) Genetic variation within the NR1H2 gene encoding liver X receptor beta associates with insulin secretion in subjects at increased risk for type 2 diabetes. J Mol Med (Berl) 89:75–81. doi:10.1007/s00109-010-0687-1 Kirchgessner TG, Martin R, Sleph P, Grimm D, Liu X, Lupisella J, Smalley J, Narayanan R, Xie Y, Ostrowski J, Cantor GH, Mohan R, Kick E (2015) Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRalpha Activity and a Favorable Window in Nonhuman Primates. J Pharmacol Exp Ther 352:305–314. doi:10.1124/jpet.114.219923 Kiss E, Kranzlin B, Wagenblabeta K, Bonrouhi M, Thiery J, Grone E, Nordstrom V, Teupser D, Gretz N, Malle E, Grone HJ (2013) Lipid droplet accumulation is associated with an increase in hyperglycemia-induced renal damage: prevention by liver X receptors. Am J Pathol 182:727–741. doi:10.1016/j.ajpath.2012.11.033 Korach-Andre M, Archer A, Barros RP, Parini P, Gustafsson JA (2011) Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proc Natl Acad Sci USA 108:403–408. doi:10.1073/pnas.1017884108 Korach-Andre M, Parini P, Larsson L, Arner A, Steffensen KR, Gustafsson JA (2010) Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57Bl/6 female mice. Am J Physiol Endocrinol Metab 298:E167–E178. doi:10.1152/ajpendo.00184.2009 Kuipers I, Li J, Vreeswijk-Baudoin I, Koster J, van der Harst P, Sillje HH, Kuipers F, van Veldhuisen DJ, van Gilst WH, de Boer RA (2010) Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail 12:1042–1050. doi:10.1093/eurjhf/hfq109;10.1093/eurjhf/hfq109 Kuipers I, van der Harst P, Kuipers F, van Genne L, Goris M, Lehtonen JY, van Veldhuisen DJ, van Gilst WH, de Boer RA (2010) Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin-aldosterone system. Lab Invest 90:630–636. doi:10.1038/labinvest.2010.7 Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, Saez E, Tontonoz P (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100:5419–5424. doi:10.1073/pnas.0830671100 Legry V, Cottel D, Ferrieres J, Chinetti G, Deroide T, Staels B, Amouyel P, Meirhaeghe A (2008) Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations. Int J Obes (Lond) 32:421–428. doi:10.1038/sj.ijo.0803705 Lei P, Baysa A, Nebb HI, Valen G, Skomedal T, Osnes JB, Yang Z, Haugen F (2013) Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury. Basic Res Cardiol 108:323. doi:10.1007/s00395-012-0323-z Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P (2007) GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol 151:450–456. doi:10.1038/sj.bjp.0707241 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK (1996) The progression from hypertension to congestive heart failure. JAMA 275:1557–1562 Li G, Biju KC, Xu X, Zhou Q, Chen C, Valente AJ, He W, Reddick RL, Freeman GL, Ahuja SS, Clark RA, Li S (2011) Macrophage LXRalpha gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-/-) mice. Gene Ther 18:835–841. doi:10.1038/gt.2011.29 Li X, Song Y, Han Y, Wang D, Zhu Y (2012) Liver X receptor agonist alleviated high glucose-induced endothelial progenitor cell dysfunction via inhibition of reactive oxygen species and activation of AMP-activated protein kinase. Microcirculation 19:547–553. doi:10.1111/j.1549-8719.2012.00186.x Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, Lutfy K, Friedman TC (2006) Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147:5061–5068 (en.2006-0243 [pii]) Lund LH, Benson L, Dahlstrom U, Edner M (2012) Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308:2108–2117. doi:10.1001/jama.2012.14785 Lund LH, Benson L, Dahlstrom U, Edner M, Friberg L (2014) Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 312:2008–2018. doi:10.1001/jama.2014.15241 Martini S, Eichinger F, Nair V, Kretzler M (2008) Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord 9:267–274. doi:10.1007/s11154-008-9103-3 McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC for Committee Practice Guidelines (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847. doi:10.1093/eurheartj/ehs104 McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM (2008) Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 10:149–156. doi:10.1016/j.ejheart.2007.12.010 Meng ZX, Nie J, Ling JJ, Sun JX, Zhu YX, Gao L, Lv JH, Zhu DY, Sun YJ, Han X (2009) Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia 52:125–135. doi:10.1007/s00125-008-1174-x Mooijaart SP, Kuningas M, Westendorp RG, Houwing-Duistermaat JJ, Slagboom PE, Rensen PC, van Heemst D (2007) Liver X receptor alpha associates with human life span. J Gerontol A Biol Sci Med Sci 62:343–349 (62/4/343 [pii]) Morello F, de Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma F, Anderson LM, Lawn RM, Gustafsson JA, Lopez-Ilasaca M, Pratt RE, Dzau VJ (2005) Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 115:1913–1922. doi:10.1172/JCI24594 Nagoshi T, Yoshimura M, Rosano GM, Lopaschuk GD, Mochizuki S (2011) Optimization of cardiac metabolism in heart failure. Curr Pharm Des 17:3846–3853 (BSP/CPD/E-Pub/000724 [pii]) Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ (2006) Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113:90–97 (CIRCULATIONAHA.105.560177 [pii]) Neubauer S (2007) The failing heart—an engine out of fuel. N Engl J Med 356:1140–1151. doi:10.1056/NEJMra063052 Noghero A, Perino A, Seano G, Saglio E, Lo Sasso G, Veglio F, Primo L, Hirsch E, Bussolino F, Morello F (2012) Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2. Arterioscler Thromb Vasc Biol 32:2280–2288. doi:10.1161/ATVBAHA.112.250621 Opie LH, Knuuti J (2009) The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 54:1637–1646. doi:10.1016/j.jacc.2009.07.024;10.1016/j.jacc.2009.07.024 Papageorgiou AP, Heggermont W, Rienks M, Carai P, Langouche L, Verhesen W, De Boer RA, Heymans S (2015) Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis. Cardiovasc Res 107:78–88. doi:10.1093/cvr/cvv157 Patel M, Wang XX, Magomedova L, John R, Rasheed A, Santamaria H, Wang W, Tsai R, Qiu L, Orellana A, Advani A, Levi M, Cummins CL (2014) Liver X receptors preserve renal glomerular integrity under normoglycaemia and in diabetes in mice. Diabetologia 57:435–446. doi:10.1007/s00125-013-3095-6 Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:263–271. doi:10.1016/j.jacc.2013.02.092 Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550 (ehm037 [pii]) Peet DJ, Janowski BA, Mangelsdorf DJ (1998) The LXRs: a new class of oxysterol receptors. Curr Opin Genet Dev 8:571–575 Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ (1998) Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93:693–704 (S0092-8674(00)81432-4 [pii]) Pencheva N, Buss CG, Posada J, Merghoub T, Tavazoie SF (2014) Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 156:986–1001. doi:10.1016/j.cell.2014.01.038 Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M (2006) Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55:2502–2509 (55/9/2502 [pii]) Rankinen T, Sarzynski MA, Ghosh S, Bouchard C (2015) Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors? Circ Res 116:909–922. doi:10.1161/CIRCRESAHA.116.302888 Rebe C, Raveneau M, Chevriaux A, Lakomy D, Sberna AL, Costa A, Bessede G, Athias A, Steinmetz E, Lobaccaro JM, Alves G, Menicacci A, Vachenc S, Solary E, Gambert P, Masson D (2009) Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ Res 105:393–401. doi:10.1161/CIRCRESAHA.109.201855 Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ (2000) Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14:2819–2830 Repa JJ, Mangelsdorf DJ (2002) The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 8:1243–1248. doi:10.1038/nm1102-1243 Rooki H, Ghayour-Mobarhan M, Haerian MS, Ebrahimi M, Azimzadeh P, Heidari-Bakavoli A, Mirfakhraei R, Tavallaie S, Mirhafez R, Ferns G, Zali MR (2013) Lack of association between LXRalpha and LXRbeta gene polymorphisms and prevalence of metabolic syndrome: a case-control study of an Iranian population. Gene 532:288–293. doi:10.1016/j.gene.2013.09.107 Ross SE, Erickson RL, Gerin I, DeRose PM, Bajnok L, Longo KA, Misek DE, Kuick R, Hanash SM, Atkins KB, Andresen SM, Nebb HI, Madsen L, Kristiansen K, MacDougald OA (2002) Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol 22:5989–5999 Ruggenenti P, Cravedi P, Remuzzi G (2012) Mechanisms and treatment of CKD. J Am Soc Nephrol 23:1917–1928. doi:10.1681/ASN.2012040390 Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B (2000) Role of LXRs in control of lipogenesis. Genes Dev 14:2831–2838 Schuster GU, Parini P, Wang L, Alberti S, Steffensen KR, Hansson GK, Angelin B, Gustafsson JA (2002) Accumulation of foam cells in liver X receptor-deficient mice. Circulation 106:1147–1153 Sharma K, Kass DA (2014) Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 115:79–96. doi:10.1161/CIRCRESAHA.115.302922 Shi Y, Xu X, Tan Y, Mao S, Fang S, Gu W (2014) A liver-X-receptor ligand, T0901317, attenuates IgE production and airway remodeling in chronic asthma model of mice. PLoS ONE 9:e92668. doi:10.1371/journal.pone.0092668 Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A (2004) The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 13:163–170 Sironi L, Mitro N, Cimino M, Gelosa P, Guerrini U, Tremoli E, Saez E (2008) Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett 582:3396–3400. doi:10.1016/j.febslet.2008.08.035 Solaas K, Legry V, Retterstol K, Berg PR, Holven KB, Ferrieres J, Amouyel P, Lien S, Romeo J, Valtuena J, Widhalm K, Ruiz JR, Dallongeville J, Tonstad S, Rootwelt H, Halvorsen B, Nenseter MS, Birkeland KI, Thorsby PM, Meirhaeghe A, Nebb HI (2010) Suggestive evidence of associations between liver X receptor beta polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe). BMC Med Genet 11:144. doi:10.1186/1471-2350-11-144 Song C, Kokontis JM, Hiipakka RA, Liao S (1994) Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc Natl Acad Sci USA 91:10809–10813 Spillmann F, Van Linthout S, Miteva K, Lorenz M, Stangl V, Schultheiss HP, Tschope C (2014) LXR agonism improves TNF-alpha-induced endothelial dysfunction in the absence of its cholesterol-modulating effects. Atherosclerosis 232:1–9. doi:10.1016/j.atherosclerosis.2013.10.001 Spyridon M, Moraes LA, Jones CI, Sage T, Sasikumar P, Bucci G, Gibbins JM (2011) LXR as a novel antithrombotic target. Blood 117:5751–5761. doi:10.1182/blood-2010-09-306142 Stender S, Frikke-Schmidt R, Anestis A, Kardassis D, Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A (2011) Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population. Arterioscler Thromb Vasc Biol 31:2990–2996. doi:10.1161/ATVBAHA.111.223867 Stenson BM, Ryden M, Venteclef N, Dahlman I, Pettersson AM, Mairal A, Astrom G, Blomqvist L, Wang V, Jocken JW, Clement K, Langin D, Arner P, Laurencikiene J (2011) Liver X receptor (LXR) regulates human adipocyte lipolysis. J Biol Chem 286:370–379. doi:10.1074/jbc.M110.179499 Stulnig TM, Steffensen KR, Gao H, Reimers M, Dahlman-Wright K, Schuster GU, Gustafsson JA (2002) Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol Pharmacol 62:1299–1305 Tachibana H, Ogawa D, Matsushita Y, Bruemmer D, Wada J, Teshigawara S, Eguchi J, Sato-Horiguchi C, Uchida HA, Shikata K, Makino H (2012) Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J Am Soc Nephrol 23:1835–1846. doi:10.1681/ASN.2012010022;10.1681/ASN.2012010022 Tamura K, Chen YE, Horiuchi M, Chen Q, Daviet L, Yang Z, Lopez-Ilasaca M, Mu H, Pratt RE, Dzau VJ (2000) LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc Natl Acad Sci USA 97:8513–8518. doi:10.1073/pnas.100519097 Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Schulman IG (2002) Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 99:11896–11901. doi:10.1073/pnas.182199799 Taube A, Schlich R, Sell H, Eckardt K, Eckel J (2012) Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 302:H2148–H2165. doi:10.1152/ajpheart.00907.2011 Tontonoz P, Mangelsdorf DJ (2003) Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17:985–993. doi:10.1210/me.2003-0061 Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T (2009) LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J Lipid Res 50:301–311. doi:10.1194/jlr.M800374-JLR200 Viennois E, Pommier AJ, Mouzat K, Oumeddour A, El Hajjaji FZ, Dufour J, Caira F, Volle DH, Baron S, Lobaccaro JM (2011) Targeting liver X receptors in human health: deadlock or promising trail? Expert Opin Ther Targets 15:219–232. doi:10.1517/14728222.2011.547853 Walcher D, Vasic D, Heinz P, Bach H, Durst R, Hausauer A, Hombach V, Marx N (2010) LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration. Basic Res Cardiol 105:487–494. doi:10.1007/s00395-010-0092-5 Walczak R, Joseph SB, Laffitte BA, Castrillo A, Pei L, Tontonoz P (2004) Transcription of the vascular endothelial growth factor gene in macrophages is regulated by liver X receptors. J Biol Chem 279:9905–9911. doi:10.1074/jbc.M310587200 Wang Y, Li C, Cheng K, Zhang R, Narsinh K, Li S, Li X, Qin X, Zhang R, Li C, Su T, Chen J, Cao F (2014) Activation of liver X receptor improves viability of adipose-derived mesenchymal stem cells to attenuate myocardial ischemia injury through TLR4/NF-kappaB and Keap-1/Nrf-2 signaling pathways. Antioxid Redox Signal. doi:10.1089/ars.2013.5683 Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4:44–52. doi:10.1161/CIRCHEARTFAILURE.109.931451 Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ (1995) LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 9:1033–1045 Witteles RM, Fowler MB (2008) Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51:93–102. doi:10.1016/j.jacc.2007.10.021;10.1016/j.jacc.2007.10.021 Wu S, Yin R, Ernest R, Li Y, Zhelyabovska O, Luo J, Yang Y, Yang Q (2009) Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 84:119–126. doi:10.1093/cvr/cvp180;10.1093/cvr/cvp180 Yu J, Wang Q, Wang H, Lu W, Li W, Qin Z, Huang L (2014) Activation of liver X receptor enhances the proliferation and migration of endothelial progenitor cells and promotes vascular repair through PI3 K/Akt/eNOS signaling pathway activation. Vascul Pharmacol 62:150–161. doi:10.1016/j.vph.2014.05.010 Zelcer N, Hong C, Boyadjian R, Tontonoz P (2009) LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325:100–104. doi:10.1126/science.1168974 Zelcer N, Tontonoz P (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116:607–614. doi:10.1172/JCI27883 Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom SR, Kliewer SA, Mangelsdorf DJ, Schulman IG (2012) Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest 122:1688–1699. doi:10.1172/JCI59817;10.1172/JCI59817 Zhou YF, Zhang J, Li ZX, Miao JL, Yin QX, Li JJ, Zhang XY, Li YY, Luo HL (2014) Association of liver X receptor alpha (LXRalpha) gene polymorphism and coronary heart disease, serum lipids and glucose levels. Lipids Health Dis 13:34. doi:10.1186/1476-511X-13-34 Zhu M, Fu Y, Hou Y, Wang N, Guan Y, Tang C, Shyy JY, Zhu Y (2008) Laminar shear stress regulates liver X receptor in vascular endothelial cells. Arterioscler Thromb Vasc Biol 28:527–533 (ATVBAHA.107.143487 [pii])